Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis.

Kenneth G Saag1

  • 1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, 1813 Sixth Avenue South, Birmingham, AL 35294-3296, USA. ksaag@uab.edu

Endocrinology and Metabolism Clinics of North America
|April 18, 2003
PubMed
Summary

Glucocorticoid-induced osteoporosis (GIOP) is a serious side effect of steroid therapy, particularly in rheumatoid arthritis. This review addresses controversies in GIOP epidemiology, pathogenesis, diagnosis, and prevention strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis treatment adherence trajectories, comedication patterns, and romosozumab persistence among early users: A data-driven analysis.

Bone·2026
Same author

Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Health literacy and happiness: A community-based study.

Social indicators research·2026
Same author

Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.

The lancet. Diabetes & endocrinology·2025
Same author

Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

The Journal of rheumatology·2025

Area of Science:

  • Endocrinology
  • Rheumatology
  • Bone Metabolism

Background:

  • Glucocorticoids are widely used for inflammatory conditions.
  • Glucocorticoid-induced osteoporosis (GIOP) is a significant complication.
  • Existing literature leaves several aspects of GIOP unsettled.

Purpose of the Study:

  • To address controversies surrounding glucocorticoid-induced osteoporosis.
  • To review epidemiology, pathogenesis, safe dosage, diagnosis, and prevention.

Main Methods:

  • Literature review focusing on unsettled issues in GIOP.
  • Evidence-based analysis of diagnostic and preventive strategies.

Main Results:

  • Discussion of unresolved questions in GIOP epidemiology and pathogenesis.

Related Experiment Videos

  • Exploration of defining a "safe" glucocorticoid dose.
  • Review of diagnostic methods and evidence-based prevention.

    • Conclusions:

    • Further research is needed to clarify GIOP epidemiology and pathogenesis.
    • Defining safe glucocorticoid doses and optimal diagnostic/preventive strategies remains critical.